US FDA Open To Cell Therapy ‘Assessment Aid’ That Could Speed Development Of Next-Gen Cancer Drugs
Executive Summary
A framework for sponsors and the FDA to discuss ways to extrapolate existing data to support a new cell therapy could cut the time to approval.
You may also be interested in...
Cell Therapy Development: White Paper Urges US FDA To Allow Some Shortcuts
A Friends of Cancer Research working group suggests that the US FDA can learn lessons from the approval of Gilead/Kite’s second CAR-T therapy Tecartus that can help expedited iterative development of cell therapies more broadly.
Cell Therapy Manufacturing Hurdles Could Be Solved Through AI; ‘Great Advancements’ In Next 10 Years
Artificial intelligence could be the solution to some of the process challenges with cell therapies; CBER Director Marks also suggests AI to identify safety issues with a particular vector.
Gene Therapy Sponsors Risk Additional Work With Late-Stage Manufacturing Changes
Commercial scale-up during Phase III trials could create labeling issues and force additional clinical trials, US FDA officials said.